Humana

Humana Faces Medicare Advantage Payment Reset, Expands Home-Based Cardiac Rehabilitation and Rolls Out athenaOne Platform.

Humana's Market Skepticism Validates Previous Sell Recommendation

UnitedHealth Group

CVS Health

Medicare Proposal Sends Insurance Stocks Plummeting

哈门那

Humana's 15-Minute Chart Shows RSI Oversold and KDJ Golden Cross

UnitedHealth and Humana stocks plummet after CMS rate decision.

Catalyst<ul> <li>Strong bullish signals such as Bullish Engulfing and Marubozu White in early January indicate potential upward momentum for HUM.</li></ul>Risk<ul> <li>Analysts have shown a neutral rating with inconsistencies, suggesting a lack of strong institutional confidence in HUM.</li> <li>Fund flows are showing a negative trend across all order sizes, indicating investor outflows.</li></ul>

Key Factors

Humana's stock fell 20.6% on January 27 after CMS proposed a 0.09% average payment increase for 2027 Medicare Advantage rates, far below the 4% to 6% analyst expectations. The Trump administration’s Medicare Advantage reimbursement proposal triggered a 21% drop in Humana shares, marking the steepest decline among major health insurers. Humana’s stock is trading at a trailing P/E of 10.98, below sector averages, with analyst consensus forecasting a loss in the current quarter and sharply lower earnings for the next fiscal year.

Recent Updates

HUM News